BiCNU, also known by its generic name carmustine, is a chemotherapy medication classified as an alkylating agent. It is most commonly used in the treatment of certain types of cancer, particularly brain tumors such as glioblastoma multiforme, brainstem glioma, and medulloblastoma.
BiCNU works by interfering with the normal growth and reproduction of cancer cells. As an alkylating agent, it acts by attaching to the DNA strands within the cancer cells, causing damage to the DNA and preventing the cells from dividing and multiplying. This inhibits the growth and spread of the tumor.
The medication is administered intravenously, typically in a hospital or clinical setting, by a healthcare professional experienced in chemotherapy drug administration. The dosage and treatment schedule may vary depending on the specific cancer being treated and individual patient factors.
Like most chemotherapy drugs, BiCNU is associated with potential side effects. Common side effects may include nausea, vomiting, drowsiness, hair loss, low blood cell counts, and an increased risk of infection. Other less common but more serious side effects may include lung toxicity, liver damage, kidney problems, and an increased risk of certain types of secondary cancers.
It is important for patients receiving treatment with BiCNU to be closely monitored by their healthcare team for the development of potential side effects and to receive appropriate supportive care.
